Core Viewpoint - iRhythm is optimistic about its performance in 2026 following a successful 2025, indicating strong growth potential in the medtech industry [2]. Company Insights - The management team of iRhythm, including CEO Quentin Blackford and CFO Dan Wilson, presented at a JPMorgan Medtech event, highlighting the company's achievements and future outlook [1]. - iRhythm focuses on the complexities of arrhythmia signals, which present both challenges and opportunities in the healthcare space [3]. Industry Context - The presentation emphasized the importance of accurately interpreting arrhythmia signals, which can manifest in various ways, underscoring the need for advanced diagnostic solutions in the medtech sector [3].